東華大學圖書館 |

Giant Magnetoresistive Biosensors for Point-of-Care and Personalized Pain Medicine.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Giant Magnetoresistive Biosensors for Point-of-Care and Personalized Pain Medicine./
作者:	Cortade, Dana Lee.
面頁冊數:	1 online resource (109 pages)
附註:	Source: Dissertations Abstracts International, Volume: 84-05, Section: A.
Contained By:	Dissertations Abstracts International84-05A.
標題:	Innovations. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=29756188click for full text (PQDT)
ISBN:	9798357503275

Giant Magnetoresistive Biosensors for Point-of-Care and Personalized Pain Medicine.
Cortade, Dana Lee.

Giant Magnetoresistive Biosensors for Point-of-Care and Personalized Pain Medicine. - 1 online resource (109 pages)

Source: Dissertations Abstracts International, Volume: 84-05, Section: A.

Thesis (Ph.D.)--Stanford University, 2022.

Includes bibliographical references

Currently, there is an opioid epidemic sweeping the United States of America, as well as many countries around the world, resulting in more annual opioid overdose deaths in the USA than deaths from firearms or automobile accidents. One common pathway for opioids entering the hands of opioid naive individuals is through the prescription of opioids for postoperative pain management, which can develop into opioid misuse and chronic opioid use. Recent advances in point-of-care (POC) technologies offer an opportunity to combat the epidemic through innovations in pain medicine, reducing the need for prescription opioids through the careful management of pain pre- and post- operatively. Using versatile and multiplexable giant magnetoresistive biosensor arrays, we demonstrate two tools which can enable clinicians to proactively optimize opioid delivery postoperatively through POC opioid monitoring and reduce opioid use through targeted referrals for non-pharmacological adjuvant treatments like hypnosis.The first tool demonstrates that giant magnetoresistive (GMR) nanosensors offer a quantitative, sensitive, and rapid solution for low-cost, sample-to-answer opioid detection at the POC. We utilized the robust nature of GMR nanosensors by developing a competitive morphine assay and characterizing it in saliva, blood, and plasma. We then implemented the assay on a fully automated POC GMR platform and demonstrated its duality to detect either morphine or hydromorphone using only 180μl of direct saliva without the need for pre-processing. In 35 minutes from sample addition to result, the automated platform was controlled via smartphone and had seamless transmission of results via Bluetooth. The fully automated POC assay had a limit of detection of 3.43ng/mL for morphine and 3.49ng/mL for hydromorphone. We show that the low-cost, 80-plex GMR nanosensor array coupled with the automated POC platform can enable future development of multiplexed drug screening tools that can be deployed in clinical settings using a wide variety of noninvasive matrices.The second tool developed in this work addresses the need for targeted hypnosis referrals for pain treatment, known as hypnotic analgesia. Hypnotizability is a stable trait that moderates the benefit of hypnosis for treating pain, but limited availability of hypnotizability testing deters widespread use of hypnosis. Through our work, inexpensive genotyping of 4 single nucleotide polymorphisms (SNPs) in the catechol-omethyltransferase (COMT) gene was performed using giant magnetoresistive biosensors to determine if hypnotizable individuals can be identified for targeted hypnosis referrals. We show that this tool is 100% accurate compared with pyrosequencing, and we use it to genotype three cohorts of patient samples involved in hypnosis studies. We show that individuals with the proposed 'optimal' COMT diplotypes, 89.5% score highly on the Hypnotic Induction Profile (OR = 6.12, 95%CI = 1.26-28.75), which identified 40.5% of the treatable population. Additionally, we found that mean hypnotizability scores of the optimal group were significantly higher than the total population (p = 0.015 effect size = 0.60), an effect that was present in females (p = 0.0015, effect size = 0.83), but not in males (p = 0.28). Then in an exploratory cohort, we found that optimal individuals also reported significantly higher postoperative pain scores (p = 0.0003, effect size = 1.93), indicating a greater need for treatment.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2023

Mode of access: World Wide Web

ISBN: 9798357503275Subjects--Topical Terms:

754112
Innovations.
Index Terms--Genre/Form:

542853
Electronic books.

Giant Magnetoresistive Biosensors for Point-of-Care and Personalized Pain Medicine.
LDR:04758nmm a2200337K 4500 001 2359862
005 20230917195308.5
006 m o d
007 cr mn ---uuuuu
008 241011s2022 xx obm 000 0 eng d
020 $a 9798357503275
035 $a (MiAaPQ)AAI29756188
035 $a (MiAaPQ)STANFORDbf611mb8825
035 $a AAI29756188
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a Cortade, Dana Lee. $3 3700476
245 1 0 $a Giant Magnetoresistive Biosensors for Point-of-Care and Personalized Pain Medicine.
264 0 $c 2022
300 $a 1 online resource (109 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 84-05, Section: A.
500 $a Advisor: Wang, Shan; Hong, Guosong; Spiegel, David.
502 $a Thesis (Ph.D.)--Stanford University, 2022.
504 $a Includes bibliographical references
520 $a Currently, there is an opioid epidemic sweeping the United States of America, as well as many countries around the world, resulting in more annual opioid overdose deaths in the USA than deaths from firearms or automobile accidents. One common pathway for opioids entering the hands of opioid naive individuals is through the prescription of opioids for postoperative pain management, which can develop into opioid misuse and chronic opioid use. Recent advances in point-of-care (POC) technologies offer an opportunity to combat the epidemic through innovations in pain medicine, reducing the need for prescription opioids through the careful management of pain pre- and post- operatively. Using versatile and multiplexable giant magnetoresistive biosensor arrays, we demonstrate two tools which can enable clinicians to proactively optimize opioid delivery postoperatively through POC opioid monitoring and reduce opioid use through targeted referrals for non-pharmacological adjuvant treatments like hypnosis.The first tool demonstrates that giant magnetoresistive (GMR) nanosensors offer a quantitative, sensitive, and rapid solution for low-cost, sample-to-answer opioid detection at the POC. We utilized the robust nature of GMR nanosensors by developing a competitive morphine assay and characterizing it in saliva, blood, and plasma. We then implemented the assay on a fully automated POC GMR platform and demonstrated its duality to detect either morphine or hydromorphone using only 180μl of direct saliva without the need for pre-processing. In 35 minutes from sample addition to result, the automated platform was controlled via smartphone and had seamless transmission of results via Bluetooth. The fully automated POC assay had a limit of detection of 3.43ng/mL for morphine and 3.49ng/mL for hydromorphone. We show that the low-cost, 80-plex GMR nanosensor array coupled with the automated POC platform can enable future development of multiplexed drug screening tools that can be deployed in clinical settings using a wide variety of noninvasive matrices.The second tool developed in this work addresses the need for targeted hypnosis referrals for pain treatment, known as hypnotic analgesia. Hypnotizability is a stable trait that moderates the benefit of hypnosis for treating pain, but limited availability of hypnotizability testing deters widespread use of hypnosis. Through our work, inexpensive genotyping of 4 single nucleotide polymorphisms (SNPs) in the catechol-omethyltransferase (COMT) gene was performed using giant magnetoresistive biosensors to determine if hypnotizable individuals can be identified for targeted hypnosis referrals. We show that this tool is 100% accurate compared with pyrosequencing, and we use it to genotype three cohorts of patient samples involved in hypnosis studies. We show that individuals with the proposed 'optimal' COMT diplotypes, 89.5% score highly on the Hypnotic Induction Profile (OR = 6.12, 95%CI = 1.26-28.75), which identified 40.5% of the treatable population. Additionally, we found that mean hypnotizability scores of the optimal group were significantly higher than the total population (p = 0.015 effect size = 0.60), an effect that was present in females (p = 0.0015, effect size = 0.83), but not in males (p = 0.28). Then in an exploratory cohort, we found that optimal individuals also reported significantly higher postoperative pain scores (p = 0.0003, effect size = 1.93), indicating a greater need for treatment.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2023
538 $a Mode of access: World Wide Web
650 4 $a Innovations. $3 754112
650 4 $a Emergency medical care. $3 3563184
650 4 $a Sensors. $3 3549539
650 4 $a Health care management. $3 2122906
655 7 $a Electronic books. $2 lcsh $3 542853
690 $a 0769
690 $a 0454
710 2 $a ProQuest Information and Learning Co. $3 783688
710 2 $a Stanford University. $3 754827
773 0 $t Dissertations Abstracts International $g 84-05A.
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=29756188 $z click for full text (PQDT)